相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction
Elisa Proietti et al.
INFLAMMATORY BOWEL DISEASES (2023)
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)
Rates, predictive factors and effectiveness of ustekinumab intensification to 4-or 6-weekly intervals in Crohn's disease
Lauranne A. . A. . P. Derikx et al.
DIGESTIVE AND LIVER DISEASE (2023)
Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases
Hongsheng Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis
Joseph Meserve et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Fernando Bermejo et al.
INFLAMMATORY BOWEL DISEASES (2022)
Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China
Qian Cao et al.
INFLAMMATORY BOWEL DISEASES (2022)
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis
Dahham Alsoud et al.
JOURNAL OF CROHNS & COLITIS (2022)
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
Valerie Heron et al.
Journal of the Canadian Association of Gastroenterology (2022)
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Omoniyi J. Adedokun et al.
CLINICAL THERAPEUTICS (2022)
Safety and effectiveness of ustekinumab in elderly Crohn's disease patients
Joseph Fiske et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Biologics: how far can they go in Crohn's disease?
Katie A. Dunleavy et al.
GASTROENTEROLOGY REPORT (2022)
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study
Jia-yin Yao et al.
BMC GASTROENTEROLOGY (2021)
Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All
Rahul S. Dalal et al.
INFLAMMATORY BOWEL DISEASES (2021)
Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)
JOURNAL OF DIGESTIVE DISEASES (2021)
Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease
Sebastiaan ten Bokkel Huinink et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
Stephen B. Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2020)
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Vince B. C. Biemans et al.
JOURNAL OF CROHNS & COLITIS (2020)
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
Uri Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review
Javier P. Gisbert et al.
DRUGS (2020)
A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
Audrey Bennett et al.
CROHNS & COLITIS 360 (2020)
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease
Ninon Soufflet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx et al.
JOURNAL OF CROHNS & COLITIS (2019)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn's Disease
Eran Zittan et al.
JOURNAL OF CROHNS & COLITIS (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn's Disease
Philippe Marteau et al.
JOURNAL OF CROHNS & COLITIS (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab in Crohn's disease: evidence to date and place in therapy
Tal Engel et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab
Kotaro Ogawa et al.
JOURNAL OF CROHNS & COLITIS (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)